Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: 161533 TriKE fusion protein - GT Biopharma/Altor BioScience

Next Previous
Search
Drug Profile

Research programme: 161533 TriKE fusion protein - GT Biopharma/Altor BioScience

Alternative Names: 161533; 161533 TriKE fusion protein; 161533 TriKE molecule; CD16/IL-15/CD33; CD16/IL-15/CD33 (161533) tri-specific killer cell engager (TriKE)

Latest Information Update: 28 Jul 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Altor BioScience Corporation; OXIS International
  • Developer Altor BioScience Corporation; GT Biopharma
  • Class Antineoplastics; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action CD33 antigen inhibitors; IgG receptor antagonists; Immunologic cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 28 Jul 2021 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
  • 07 Aug 2017 Oxis International is now called GT Biopharma
  • 07 Jul 2017 University of Minnesota plans a phase I/II trial for Haematological malignancies (CD33+, Second-line therapy or greater) in USA (IV, infusion) in USA in October 2017 (NCT03214666)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top